TOMI Environmental Solutions 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy TOMZ?
Source: Yahoo Finance
- Commercial Installation Achievement: TOMI Environmental Solutions achieved its first commercial installation of the SteraMist Integrated System in 2025, completing four fully operational installations by year-end, marking significant progress in the biopharmaceutical sector despite a decline in overall revenue.
- Key Contract Secured: The company secured a $500,000 purchase contract with a global biopharmaceutical leader, further expanding its market share in the cell and gene therapy sector, although it faces liquidity challenges with only $88,000 in cash at year-end.
- Gross Margin Improvement: The gross margin improved to approximately 55% in 2025, up from 46% in 2024, reflecting lower cost of sales and reduced inventory reserves, despite reporting a net loss of $3.7 million.
- Market Challenges: The company faces challenges such as tariffs, political uncertainty, and the impact of the Middle East crisis, which have delayed customer capital expenditure projects; despite a strong pipeline, the stock price declined to $0.78 by the end of 2025, reflecting market concerns over financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TOMZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TOMZ
Wall Street analysts forecast TOMZ stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.583
Low
3.50
Averages
3.50
High
3.50
Current: 0.583
Low
3.50
Averages
3.50
High
3.50
About TOMZ
TOMI Environmental Solutions, Inc. is a bacteria decontamination and infectious disease control company. The Company is engaged in offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. The Company utilizes its Binary Ionization Technology (BIT) platform through its SteraMist brand of products. Its flagship product, SteraMist, uses its patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. SteraMist generates ionized Hydrogen Peroxide (iHP) using cold plasma science. Its products and services include SteraPak, SteraMist Surface Unit, SteraMist Environment System, SteraMist Total Disinfection Cart, SteraMist Transport, NV+, SteraMist Custom Engineered System, Hybrid, SteraMist Integrated System, Stainless Steel 90 Degree Applicator and iHP Corporate Service Decontamination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TOMI Environmental Solutions Q4 2025 Earnings Call Insights
- Revenue and Loss Overview: Revenue for 2025 was $5.6 million, down from $7.7 million in 2024, primarily due to the timing of customer equipment purchases, although gross margin improved from 46% to 55%, indicating better cost control.
- Technology and Market Expansion: The SIS system achieved its first commercial installation in June 2025 and ended the year with four fully operational installations, alongside a $500,000 purchase contract with a global biopharmaceutical leader, marking significant commercialization progress in automation.
- Future Outlook and Targets: CEO estimates 2026 revenue will reach $12 million, with a total opportunity book of $16 million for integration projects and $20 million for iHP, showcasing strong growth potential in the market.
- Operational Efficiency Improvement: Operating expenses decreased by approximately 10% to $6.9 million in 2025, and the company is actively pushing open BIT solution orders and annual service offerings, with a significant increase in support service demand reflected in a 16% backlog increase.
See More
TOMI Environmental Solutions 2025 Earnings Highlights
- Commercial Installation Achievement: TOMI Environmental Solutions achieved its first commercial installation of the SteraMist Integrated System in 2025, completing four fully operational installations by year-end, marking significant progress in the biopharmaceutical sector despite a decline in overall revenue.
- Key Contract Secured: The company secured a $500,000 purchase contract with a global biopharmaceutical leader, further expanding its market share in the cell and gene therapy sector, although it faces liquidity challenges with only $88,000 in cash at year-end.
- Gross Margin Improvement: The gross margin improved to approximately 55% in 2025, up from 46% in 2024, reflecting lower cost of sales and reduced inventory reserves, despite reporting a net loss of $3.7 million.
- Market Challenges: The company faces challenges such as tariffs, political uncertainty, and the impact of the Middle East crisis, which have delayed customer capital expenditure projects; despite a strong pipeline, the stock price declined to $0.78 by the end of 2025, reflecting market concerns over financial performance.
See More
TOMI Environmental Solutions FY Earnings Report Analysis
- Disappointing Earnings: TOMI Environmental Solutions reported a fiscal year GAAP EPS of -$0.19, indicating significant challenges in profitability and reflecting a deterioration in financial health.
- Significant Revenue Decline: The company reported revenue of $5.63 million, a 27.3% year-over-year decrease, missing expectations by $1.3 million, suggesting weak market demand and a need for sales strategy adjustments.
- Negative Market Reaction: The failure to meet earnings expectations has dampened investor confidence in the company's future, potentially leading to further stock price declines that could impact its financing capabilities and market position.
- Need for Strategic Adjustment: In light of the dual pressures on revenue and profitability, TOMI must reassess its market strategies and operational efficiencies to navigate the current economic landscape and restore growth momentum.
See More
TOMI Secures Disinfectant Authorization in Netherlands
- Product Authorization Milestone: TOMI's Binary Ionization Technology (BIT) has received formal approval in the Netherlands, marking the company's first product authorization within an EU member state, which is expected to enhance its market penetration in Europe, particularly in healthcare and commercial sectors.
- Market Expansion Potential: The BIT solution's authorization covers SteraMist room fogging and surface spraying equipment, effectively addressing bacteria, yeasts, and mycobacteria, thereby meeting the demands of multiple industries including medical, industrial, and hospitality, which is anticipated to significantly boost the company's market share in these high-demand areas.
- Mutual Recognition Advantage: Under the EU's Biocidal Products Regulation (BPR), approval in one member state supports a streamlined mutual recognition process in others, expected to accelerate TOMI's market entry in countries like Austria, Germany, and France, reducing the time and costs associated with repeated authorizations.
- Strategic Partnership Acceleration: The partnership with Netherlands-based Ster-Pharma, established in 2019, is now poised to rapidly advance the deployment of SteraMist iHP disinfection products in key sectors following this formal authorization, further solidifying TOMI's strategic position in the European market.
See More
TOMI Partners with Total Clean Air for European Market Expansion
- Strategic Partnership Agreement: TOMI Environmental Solutions has formed a strategic partnership with Total Clean Air, which will serve as TOMI's Preferred European Partner for sales and technical support of the SteraMist iHP decontamination technology, aimed at addressing the surging demand for high-level disinfection in the life sciences and pharmaceutical sectors.
- Significant Market Potential: The UK infection control market is projected to exceed $6 billion by 2031, and TCA's involvement is expected to enhance TOMI's market share in this rapidly growing sector, thereby strengthening its competitive position in Europe.
- Technical Support and Services: TCA will manage the full customer lifecycle, including annual calibration and routine inspections, ensuring a high-quality service model that meets increasingly stringent MHRA regulatory requirements and supports the adoption of rapid sterility testing methods.
- Demonstration and Trial Program: Under the new partnership, SteraMist equipment will be showcased at TCA's showroom in the UK for hands-on evaluation, which is anticipated to attract a diverse range of end-users, including pharmaceutical, biotech, and medical device manufacturers, further driving market penetration.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
TOMI Environmental Solutions Q4 2025 Earnings Call Insights
- Revenue and Loss Overview: Revenue for 2025 was $5.6 million, down from $7.7 million in 2024, primarily due to the timing of customer equipment purchases, although gross margin improved from 46% to 55%, indicating better cost control.
- Technology and Market Expansion: The SIS system achieved its first commercial installation in June 2025 and ended the year with four fully operational installations, alongside a $500,000 purchase contract with a global biopharmaceutical leader, marking significant commercialization progress in automation.
- Future Outlook and Targets: CEO estimates 2026 revenue will reach $12 million, with a total opportunity book of $16 million for integration projects and $20 million for iHP, showcasing strong growth potential in the market.
- Operational Efficiency Improvement: Operating expenses decreased by approximately 10% to $6.9 million in 2025, and the company is actively pushing open BIT solution orders and annual service offerings, with a significant increase in support service demand reflected in a 16% backlog increase.
See More
TOMI Environmental Solutions 2025 Earnings Highlights
- Commercial Installation Achievement: TOMI Environmental Solutions achieved its first commercial installation of the SteraMist Integrated System in 2025, completing four fully operational installations by year-end, marking significant progress in the biopharmaceutical sector despite a decline in overall revenue.
- Key Contract Secured: The company secured a $500,000 purchase contract with a global biopharmaceutical leader, further expanding its market share in the cell and gene therapy sector, although it faces liquidity challenges with only $88,000 in cash at year-end.
- Gross Margin Improvement: The gross margin improved to approximately 55% in 2025, up from 46% in 2024, reflecting lower cost of sales and reduced inventory reserves, despite reporting a net loss of $3.7 million.
- Market Challenges: The company faces challenges such as tariffs, political uncertainty, and the impact of the Middle East crisis, which have delayed customer capital expenditure projects; despite a strong pipeline, the stock price declined to $0.78 by the end of 2025, reflecting market concerns over financial performance.
See More
TOMI Environmental Solutions FY Earnings Report Analysis
- Disappointing Earnings: TOMI Environmental Solutions reported a fiscal year GAAP EPS of -$0.19, indicating significant challenges in profitability and reflecting a deterioration in financial health.
- Significant Revenue Decline: The company reported revenue of $5.63 million, a 27.3% year-over-year decrease, missing expectations by $1.3 million, suggesting weak market demand and a need for sales strategy adjustments.
- Negative Market Reaction: The failure to meet earnings expectations has dampened investor confidence in the company's future, potentially leading to further stock price declines that could impact its financing capabilities and market position.
- Need for Strategic Adjustment: In light of the dual pressures on revenue and profitability, TOMI must reassess its market strategies and operational efficiencies to navigate the current economic landscape and restore growth momentum.
See More
TOMI Secures Disinfectant Authorization in Netherlands
- Product Authorization Milestone: TOMI's Binary Ionization Technology (BIT) has received formal approval in the Netherlands, marking the company's first product authorization within an EU member state, which is expected to enhance its market penetration in Europe, particularly in healthcare and commercial sectors.
- Market Expansion Potential: The BIT solution's authorization covers SteraMist room fogging and surface spraying equipment, effectively addressing bacteria, yeasts, and mycobacteria, thereby meeting the demands of multiple industries including medical, industrial, and hospitality, which is anticipated to significantly boost the company's market share in these high-demand areas.
- Mutual Recognition Advantage: Under the EU's Biocidal Products Regulation (BPR), approval in one member state supports a streamlined mutual recognition process in others, expected to accelerate TOMI's market entry in countries like Austria, Germany, and France, reducing the time and costs associated with repeated authorizations.
- Strategic Partnership Acceleration: The partnership with Netherlands-based Ster-Pharma, established in 2019, is now poised to rapidly advance the deployment of SteraMist iHP disinfection products in key sectors following this formal authorization, further solidifying TOMI's strategic position in the European market.
See More
TOMI Partners with Total Clean Air for European Market Expansion
- Strategic Partnership Agreement: TOMI Environmental Solutions has formed a strategic partnership with Total Clean Air, which will serve as TOMI's Preferred European Partner for sales and technical support of the SteraMist iHP decontamination technology, aimed at addressing the surging demand for high-level disinfection in the life sciences and pharmaceutical sectors.
- Significant Market Potential: The UK infection control market is projected to exceed $6 billion by 2031, and TCA's involvement is expected to enhance TOMI's market share in this rapidly growing sector, thereby strengthening its competitive position in Europe.
- Technical Support and Services: TCA will manage the full customer lifecycle, including annual calibration and routine inspections, ensuring a high-quality service model that meets increasingly stringent MHRA regulatory requirements and supports the adoption of rapid sterility testing methods.
- Demonstration and Trial Program: Under the new partnership, SteraMist equipment will be showcased at TCA's showroom in the UK for hands-on evaluation, which is anticipated to attract a diverse range of end-users, including pharmaceutical, biotech, and medical device manufacturers, further driving market penetration.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
